In particular, they focused on the withdrawal of the PVT1 ceRNA activity functioning as miR-200 sponge in breast cancer tissues, betting on a titration mechanism as the main culprit (i.e., large changes in the ceRNA expression levels either overcome, or relieve, the miRNA repression on competing RNAs; similarly, a very large miRNA over-expression may abolish competition). This evidence concerns the gene PVT1 and breast carcinoma.